Please ensure Javascript is enabled for purposes of website accessibility

Report: New Zealand Overturning Cannabis Vaporizer Ban

By Eric Volkman - Jan 21, 2020 at 4:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The plan comes months before the country is to enact its legalization of medical marijuana.

New Zealand appears to be on the brink of relegalizing cannabis vaporizers after passing a ban against the devices.

According to a report published Tuesday on MJBizDaily.com, New Zealand plans to overturn its law banning such products. This development dovetails with the country's legalization of medical cannabis, which is set to take effect in April.

Citing part of the law the ban falls under, an unnamed Health Ministry spokesperson said the nation's "cabinet has agreed to replace the Misuse of Drugs Utensils Notice with a notice that enables the import of vaporizers that have been approved as medical devices by an overseas regulator."

A hand activating a vaporizer.

Image source: Getty Images

There was no indication which "overseas regulator" or regulators, if any, are favored by the ministry. There was also no indication if the New Zealand authorities have any particular vape manufacturers in mind.

Vaping products will be crucial to the success of medical cannabis in New Zealand because smokeable cannabis like flower will not be legally allowed. Cannabis vaporizers will be allowed to be produced in New Zealand, however they will need to be officially approved -- presumably by the Health Ministry -- as medical devices. This will likely take some time, hence the initial need for imported products.

In Canada, which is a leading nation for cannabis due to legalizing both medical and recreational cannabis nationwide, six vaporizers are licensed for medical use. Of these, three are made by Canopy Growth (CGC 0.53%) subsidiary Storz & Bickel. Canopy Growth bought the German company in 2018 in a deal worth up to 145 million Canadian dollars ($161 million) at the time.

Canopy Growth, a top cannabis company, has not commented on the developments in New Zealand.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$3.79 (0.53%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.